Life sciences industry outlook
Key takeaways
Artificial intelligence has quickly become one of the most important areas of focus for nearly all industries, and its implications for life sciences are particularly significant. Across drug discovery, medical devices, clinical development and regulatory strategy, AI has the potential to accelerate innovation, improve decision making and reshape how companies allocate capital and manage operations.
As AI moves from an emerging technology to a business imperative, life sciences companies that lag in adoption may risk falling behind competitors, while those that pair AI capabilities with scientific expertise, high-quality data and regulatory readiness will be better positioned to create long-term competitive advantage.
In this outlook, we explore how AI is transforming biopharma, medtech and life sciences services, and what this shift means for the middle market companies navigating these sectors.
Biopharma: AI reshapes the path to innovation
One of the greatest challenges for biopharma companies has been the time, cost and uncertainty involved in bringing a therapy from discovery through clinical development. AI is helping the sector tackle that challenge head-on as drug discovery shifts from a largely iterative, trial-and-error process to a more computationally driven model. That shift is enabling companies to:
- Screen large libraries of compounds.
- Identify promising targets.
- Evaluate a candidate’s probability of success before committing significant resources to physical laboratory experiments.
By improving decision making earlier in the discovery process, AI can reduce development timelines, lower costs and increase the likelihood that higher-quality candidates advance into the clinic. Under the traditional development model, progressing from drug discovery to the studies needed to support an investigational new drug application can take several years; however, AI has the potential to shorten that timeline. Although no AI-discovered drug has yet received U.S. Food and Drug Administration approval, the IQVIA Global R&D Trends 2026 report found that over the most recent three-year period, the Phase I success rate for AI-enabled programs was 75%, a significant improvement over the rate for non-AI-enabled programs.
Compressing this timeline and improving success rates are among the clearest advantages of AI-enabled drug discovery. For biopharma companies, reaching key regulatory and clinical milestones sooner can translate into lower development costs, improved odds of advancing higher-probability programs, and earlier inflection points for fundraising, partnering and strategic transaction activity.
Another benefit is that companies may be able to reach critical endpoints and value-creating milestones more quickly, which can serve as important inflection points for fundraising, partnering and strategic transaction activity. AI-enabled drug discovery has also made financing and mergers and acquisitions more attractive.
Investor interest remains strong, even though none of the drugs approved by the FDA have originated entirely through AI. According to PitchBook deal activity data from January 2019 through August 2026, indexed to 2019 levels, biopharma and pharmaceutical companies with a significant focus on AI and machine learning (ML) have experienced faster funding growth than companies without an AI focus.
Improving capital efficiency for middle market biopharma companies
Emerging and midsize biopharma companies often operate with more limited funding, infrastructure and technical resources than larger competitors, making capital efficiency especially critical. AI can enable better go/no-go decisions earlier in discovery and help teams prioritize stronger candidates. However, realizing these benefits requires disciplined execution, including:
- Access to high-quality data
- Appropriate scientific and regulatory oversight
- Cybersecurity and privacy controls
- Governance processes that support defensible use of AI-derived insights
While AI will not eliminate the scientific, regulatory or funding risks inherent in drug development, companies that successfully integrate computational capabilities with strong biology, disciplined clinical strategy and regulatory planning will be better positioned to attract capital, pursue partnerships and compete in an increasingly innovation-driven market.
Medtech: AI transforms clinical decision making
AI/ML-enabled medical devices are improving detection capabilities, and over time are expected to integrate data from patient monitoring, surgical systems and other clinical sources into real-time insights and advanced analytics.
Rather than simply collecting data, these devices are increasingly helping clinicians act on it through real-time alerts, risk assessments and workflow recommendations. As a result, medtech companies will increasingly need to design products around both device performance and data utility, demonstrating that AI-enabled insights can improve patient outcomes, reduce costs, streamline clinical workflows or support value-based care models.
An analysis of the FDA AI/ML-enabled medical device database revealed that there are now more than 1,500 FDA-authorized AI/ML-enabled medical devices. Authorization for these devices has increased significantly in recent years. Should that pace hold through the rest of the year, 2026 would represent the highest annual total of authorized AI/ML-enabled devices to date.
According to the FDA’s database, approximately 76% of authorized devices are intended for radiology, reflecting the sector’s reliance on large imaging datasets, pattern recognition and workflow efficiency.
Although FDA authorizations for AI/ML-enabled devices have increased, reimbursement hasn’t kept pace. The Centers for Medicare & Medicaid Services, which oversees coverage decisions for federal health programs, still lacks a broad pathway for these devices. Without a unified coverage framework, medtech companies face what’s often called “coverage purgatory.” It’s the biggest hurdle for many medtech companies in the AI/ML space.
Meaningful opportunities for middle market medtech companies
Smaller and midsize device companies may face greater execution challenges than larger players, as many must balance product development with the need for validated algorithms, reliable data access, cybersecurity, privacy protections, reimbursement planning and regulatory readiness. Even so, AI-enabled devices and analytics present a meaningful opportunity, one that can help these companies differentiate their products, support clinical workflows and demonstrate stronger value to providers and payers.
As AI adoption accelerates, companies that move beyond incremental product enhancements and demonstrate clear clinical, operational and economic value will be better positioned to capture provider demand, navigate regulatory scrutiny and attract capital in an increasingly data-driven market.
Life sciences services: AI accelerates clinical development
Clinical trials are a critical bridge between scientific discovery and regulatory approval, but their duration, complexity and cost have long been obstacles for sponsors seeking to bring therapies to market efficiently. AI can support clinical study design, management and execution by helping clinical research organizations, or CROs, improve operational efficiency, reduce trial costs and contribute to shorter development timelines. Although recent data suggests that trial durations have remained constant or have increased overall, as reported in the IQVIA Global R&D Trends 2026 report, AI has demonstrated that it can provide significant value by improving operational efficiency and transforming the way clinical trials are designed, executed and scaled.
AI adoption is expected to be a net positive for the life sciences services sector—complementing rather than replacing traditional scientific and clinical activities—by enhancing decision making, streamlining operational workflows and improving overall efficiency. AI is helping sponsors reduce timelines, control costs and improve trial success rates, and is transforming clinical trials across multiple areas, including:
- Cost management
- Data management and monitoring
- Patient recruitment and retention
- Patient selection
- Predictive analysis
- Protocol optimization and design
- Synthetic control arms
As AI-enabled discovery advances more drug candidates into the pipeline, demand for life sciences services companies may also increase, positioning those that can integrate AI capabilities with clinical expertise, regulatory discipline and scalable operations to compete more effectively in a faster-moving market.
What this means for companies
AI adoption can make middle market life sciences services companies more competitive by improving trial design, patient recruitment, data monitoring and cost management. These improvements can help CROs and other service providers meet sponsor demands for faster, more efficient development programs. Capturing that opportunity may require providers to overcome fragmented data environments, limited internal AI expertise and heightened expectations around privacy, cybersecurity, validation and regulatory documentation.
Companies that integrate AI into practical service delivery models while maintaining strong clinical, quality and compliance oversight will be better positioned to win sponsor relationships and scale alongside a growing AI-enabled development pipeline.
Regulatory outlook: AI governance becomes a competitive imperative
AI regulation in life sciences is becoming more structured as U.S. and European regulators move toward risk-based oversight, stronger transparency and lifecycle accountability. Companies adopting AI across product development, clinical research, medical devices, manufacturing and quality systems should understand the principal frameworks shaping regulatory expectations, including:
- European Medicines Agency (EMA) reflection paper on AI in the medicinal product lifecycle: Establishes risk-based expectations for AI use across the development and lifecycle of medicines
- FDA draft guidance on AI in regulatory decision making and FDA/EMA good AI practice principles: Focus on model credibility, context-of-use risk, data provenance, bias assessment, transparency, validation and ongoing monitoring
- FDA modernization and non-animal testing initiatives: Support the potential use of AI-based computational models and other new approach methodologies in nonclinical safety and efficacy assessments
- FDA total product lifecycle and computer software assurance frameworks: Address adaptive AI/ML-enabled medical devices and AI systems used in production or quality management, with an emphasis on lifecycle governance, cybersecurity and vendor oversight
- EU Artificial Intelligence Act alongside the Medical Device Regulation and In Vitro Diagnostic Medical Devices Regulation: Adds high-risk AI requirements for many AI/ML-enabled medical devices, including technical documentation, data governance, human oversight, transparency and postmarket monitoring
Building advantage in an AI-driven industry
While many of AI’s most transformative applications across the life sciences industry are still developing, the direction is clear: AI is moving from an emerging capability to a strategic requirement. Across biopharma, medtech and life sciences services, companies that can pair AI adoption with scientific expertise, high-quality data, disciplined governance and regulatory readiness will be best positioned to create a durable competitive advantage.